Accuracy and safety of the implantable Eversense CGM system, approved by the FDA in 2018, have been demonstrated in multiple clinical trials and real-world analyses. No glucometric outcomes by age have been reported.
Anonymized sensor glucose (SG) data from Eversense data management system (DMS) were analyzed for the first 582 patients with a 90‐day wear period. Mean SG, GMI, and percent time across glucose ranges were calculated for various age ranges from young adult to Medicare-age populations.
Among 582 patients, ~85 identified as TID, and ~1/3 reported being CGM naïve. Percent of time in various ranges demonstrated time in range (TIR, 70-180 mg/dL), time below ranges (<70 mg/dL and <54 mg/dL), and time above ranges (>180 mg/dL and >250 mg/dL) improved with age, with a 50% TIR in patients 18-24 years of age to 68% and 70% TIR in patients >60 and ≥65 years of age, respectively (Table). Mean GMI and SG also decreased with age. Hypoglycemia did not increase with age.
These data demonstrated that glycemic outcomes improve with age in Eversense CGM system users. The older, Medicare cohort did not have an increase in hypoglycemia compared to other adult groups, despite the lowest GMI and highest TIR. While glucometrics in young adults are not optimal, these results (in a small cohort) suggest that a long-term implantable sensor might offer this age group the opportunity to attain A1C results, as supported by GMI data, less than 8% with an acceptable risk of hypoglycemia.